Corline Biomedical AB (CLBIO.ST) released Loss for fourth quarter of -SEK5.03 million
The company's bottom line totaled -SEK5.03 million, or -SEK0.20 per share. This compares with -SEK14.16 million, or -SEK0.62 per share, last year.
The company's revenue for the period rose 4.6% to SEK2.104 million from SEK2.012 million last year.
Corline Biomedical AB earnings at a glance (GAAP) :
-Earnings: -SEK5.03 Mln. vs. -SEK14.16 Mln. last year.-EPS: -SEK0.20 vs. -SEK0.62 last year.-Revenue: SEK2.104 Mln vs. SEK2.012 Mln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.